A monoclonal antibody, designated 2E1, against human pancreatic phospholipase A 2 was produced by hybridization of myeloma cells with spieen cells of immunized BALB/c mice. The hybridomas were screened for antibody production by time-resolved fluoroirnrnunoassay (TR-FIA). The antibody was found to belong to subclass I of murine IgG. The specificity of the antibody was confirmed by immunohistochemistry of pancreatic and other tissues, by immunoblotting of a crude aqueous extract of human pancreas and purified human pancreatic phospholipase A 2 and by TR-FIA. A solid-phase time-resolved fluoroimmunoassay was developed by using the monoclonal anti-phospholipase A 2 antibody äs the catching antibody and a polyclonal sheep anti-phospholipase A 2 antibody labelled with europium äs the detecting antibody. The validity of the new TR-FIA of human pancreatic phospholipase A 2 was confirmed by using it to measure the phospholipase A 2 concentrations in serum samples from healthy subjects and from patients suffering from acute pancreatitis.
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, A . _, other mahgnant tumours of vanous types (4) . The Pancreatic phospholipase A 2 J ) is a digestive enzyme increasedconcentrationofimmunoreactive pancreatic synthesized by pancreatic acinar cells and secreted äs phospholipase A 2 in serum is a sensitive indicator of an enzymatically inactive proenzyme into the duo-acinar cell damage in acute pancreatitis and other denum, where it is transformed into an active form pancreatic injuries (5) . In patients with liver, gall by limited hydrolysis by trypsin. Only two immuno-bladder and pancreatic cancer, the elevation of serum chemicäl techniques for measuring the concentration phospholipase A 2 correlated with the stage of the of pancreatic phospholipase A 2 in serum and other disease (4) . body fluids have been developed. These methods are based on either time-resolved flüoroimmünoassay T h e purpose of the present study was to prepare (TR-FIA) (1) or radioirnmunoassay (RIA), (2, 3) , and monoclonal antibodies against human pancreatic seemploy polyclonal änti-phospholipase A 2 antibodies cretor y phospholipase A 2 , to test their specificity and raised in rabbits. Ari RIA-method employing a monoto devel°P a new immunoassay for the measurement clonal antibody was described recently (4) . Increased of the phospholipase A 2 concentration m serum. values of immunoreactive pancreatic phospholipase Time-resolved fluorescence was used äs a detecting A 2 have been found in sera of patients suffering from method in a solid-phase sandwich assay. The monoacute pancreatitis (5, 6) , pancreatic qancer (5) and donal antibod y was used as the catchin S antibod y and polyclonal anti-phospholipase A 2 antibody la-! ) Enzymes· belled with an europium (Eu) chelate was used as the Phospholipase A 2 , phosphatide 2-acylhydrolase (EC 3.1.1.4) detecting antibody. Phospholipase A 2 was purified from .human cadaver pancreas äs described earlier (8) .
Materials and Methods

Reagents
Preparation of antibodies to human pancreatic phosp holipase A 2
Monoclonal antibodies were produced according to the method of Galfre & Milstein (9) . Briefly, male mice (BALB/cKuo, from the University of Kuopio, Kuopio, Finland) were irnmunized three tirnes at two-week intervals subcutaneously with 50 g of purified human pancreatic phospholipase A 2 . For the first inv munization, the antigen was mixed with complete Freunds adjuvant (l -h l by vol.) and for the second and third immun izations with incomplete Freunds adjuvant. After the third immunization, the animals were bled and tested by TR-FIA for specific antibody. The animal that showed the highest antibody response against phospholipase A 2 at serum dilution l : 100 was boosted intravenously via the tail vein with 100 g of antigen in 100 of saline. Three days after the booster injection, the mouse was killed arid its spieen cells were harvested and fused with mouse myeloma cells (NS-1) by treatnaent with 500 ml/l PEG 4000 in KC 2000-medium containing 200 ml/l fetal calf serum. The fused cells were cultured in hypoxarithine-aminopterin-thymidine medium supplemented with 200 ml/l fetal ealf serum until myeloma cells disappeared, after which they were cultured in hypoxanthine-thymidine medium supplemented with 200 ml/l fetal calf serum. Hybridoma supernatants were tested for antibody productipn by TR-FIA. Positive cells were cloned two times by the limiting dilution method. Finally the resulting hybridömas were injected into the peritoneal cavity of BALB/c mice pretreated with pristane to obtain monoclonal antibodies in the ascitic fluid.
Antiserum to human pancreatic phospholipase A 2 was raised in a sheep. The sheep was immunized three times at three-week intervals subcutaneously with 0.1 mg of purified phospholipase A 2 in Freunds complete adjuvant. Serum was collected two weeks after the last booster injection.
The immunoglobulin subclass of the monoclonal antibody was determined in hybridoma supernatants with the Serotec Isotyping kit for monoclonal antibodies aecording to the manufacturer's instructions.
Purificatiori of antibodies
Polyclonal sheep antibodies were purified by passing the antiserum through an affinity column containing human pancreatic phospholipase A 2 coupled to CH-Sepharose 4B äs a ligand. The coupling of protein to the gel was performed according to the manufacturer's instructions. The specific anti-phospholipaße A 2 antibody was eluted with 7.5 mol/1 sodium thidcyanate in phosphate buffer (pH 7.3).
The monoclonal antibody was purified by affinity chromatography with the Protein A MAPS II kit.
Electrophoresis and immunoblotting
The specificity of the monoclonal antibody was determined by immunoblotting of purified human pancreatic phospholipase A 2 and a crude aqueous extract of human pancreas after ammonium sulphate precipitation (8) . Electrophoresis was performed on SDS-PAGE 8-25% gradient gel with the PhastSystem™ apparatus according to the manufacturer's instruc-tions. Proteins were visualizcd by Coomassie blue staining. Proleins were transferred to nitrocellulose filters with the PhastSystem semidry immunoblotting device according to the manufacturer's instructions. The Vectastain ABC-kit was used for the immunostaining of the nitrocellulose filters.
For the TR-FIA of human pancreatic phospholipase A 2 employing only polyclonal anti-phospholipase A 2 antibodies, the microtitre wells were coated with affinity-purified polyclonal sheep anti-phospholipase A 2 antibody (5 μg/200 μΐ per well) by physical adsorption overnight. Otherwise the assay procedure was the same s described above.
Immunohistochemistry
Samples of human pancreas and various other tissues were from the files of the Department of Pathology, University of 1\irku, Turku, Finland. The tissues were fixed in buffered formalin, embedded in paraffin, and sectioned at 5 μπ). The immunostaining was performed by using the monoclonal antibody 2E1 s the primary antibody and a Vectastain ABC (avidinbiotin complex) kit for detecting the site of the immunoreaction according to the manufacturer's instructions. In control stainings, the primary antibody was replaced by either bovine serum albumin or a non-related monoclonal antibody (anti-IgE antibody).
Labelling of phospholipase A 2 antibody
The affinity-purified sheep anti-phospholipase A 2 antibody was labelled with an isothiocyanate derivative of the europium chelate (Eu
,N 3 -tetraacetate) s described earlier (l, 10). The europium chelate at 53-fold molar excess was allowed to react with the affmity purified antibody. The pH was adjusted to 9.5 with l mol/1 Na 2 CO 3 solution. After an overnight incubation at 4 °C, the labelled antibody was separated from excess reagent by gel Filtration through a column l .8 cm in diameter and filled with Trisacryl GF2000 to a height of 37 cm with an additional 9 cm of Sephadex G50 on top. The column was eluted with 50 mmol/1 Tris/saline/azide buffer. About 9 moles of EU were incorporated per mole of immunoglobulin.
Coating of polystyrene microtitre plates
Microtitre plates made of polystyrene were coated with the monoclonal anti-phospholipase A 2 antibody (25 mg/1) by physical adsorption from 0.2 ml of Tris/saline/azide buffer overnight. The plates were washed two times in an automatic washing device before use.
Time-resolved fluoroimmunoassays
Measurements with TR^FIA were performed s described earlier (1). Serum samples of immunized mice and hybridoma supernatants were tested in microtitre plates coated with aflinity^purified polyclonal anti-phospholipase A 2 antiserum (l μg cpntained in 100 μΐ added to each well). The coated plates were washed four times, after which either 5 ng (100 μΐ/well) of purified pancreatic phospholipase A 2 (positive tests) or 100 μΐ of assay buffer (negative tests) were pipetted intp the wells. After incubation for l h and washing, 30 μΐ of serum dilution or hybridoma growth medi m with 70 μΐ assay buffer were added. Positive cells were detected with 100 ng (100 μΐ/well) of Eu-labelled rabbit antibodies to mouse IgG.
For the TR-FIA of human pancreatic phospholipase A 2 , 25 μΐ of serum sample or human phospholipase A 2 Standard in TR-FIA assay buffer were pipetted into the microtitre wells, which had been coated with monoclonal anti-phospholipase A 2 antibody and c ntained 175 μΐ of TR-FIA assay buffer. After l h incubation with shaking at room temperature, the wells were aspirated and washed six times, and the Eu-labelled polyclonal anti-phospholipase A 2 antibody (500 ng/well) was added. The washing Step was repeated after l h and 200 μΐ of enhancement solution was added. After 5 minutes shaking and 10 minutes Standing, fluorescence was measured with an Arcus fluorometer.
Statistics
The ninety five per cent reference interval was calculated according to the recommendations of the International Federation of Clinical Chemistry (11) . The Refval statistical analysis System (H. Solberg, Department of Clinical Chemistry, Rikshospitalet, Oslo, Norway) Software package was used for the statistical analysis and calculation of the reference interval on a microcomputer.
Results
Monoclonal antibody 2E1 against human pancreatic phospholipase A 2
One of the hybridomas, 2E1, produced an antibody that specifically reacted with human pancreatic phospholipase A 2 . The purity of the monoclonal antibody 2E1 after the affmity purification with MAPS II Kit was verified by SDS-PAGE, where it gave homogeneous protein bands with relative molecular masses of approximately 62000 (heavy chain) and 25000 (light chain). The subclass of the monoclonal antibody 2E1 was identified s IgGl.
The specificities of monoclonal and polyclonal antibodies were determined by immunohistochemistry and immunoblotting. An aqueous extract of human pancreas and purified pancreatic phospholipase A 2 were resolved by SDS-PAGE, blotted to a nitrocellulose membrane and stained with monoclonal and polyclonal antibodies. The monoclonal antibody 2E1 reacted with one protein band only in both cases. The antibody 2E1 recognized the non-reduced native form but not the reduced form of the human pancreatic phospholipase A 2 enzyme ( fig. 1) . The polyclonal sheep anti-phospholipase A 2 antiserum gave one protein band with purified human pancreatic phospholipase A 2 ( fig. 1 ). It recognized, however, one major band of apparent M T about 15000 and another weak band of higher M r in the aqueous extract of human pancreas ( fig. 1 ). Phospholipase A 2 was found in the cytoplasm of pancreatic acinar cells by immunohistochemistry using the monoclonal antibody 2E1 ( fig.  2) . No re ction was seen in pancreatic duct cells or islets of Langerhans or in other human tissues studied (liver, kidney, spieen, muscle, lymph node and thyroid). The specificity of the monoclonal antibody 2E1 was also investigated by TR-FIA ( fig. 3) of added phospholipase A 2 /amount phospholipase A 2 added ) χ 100. The analytical recoveries were 96.2% and 123.1%, respectively, with an overall mean 109.6%.
Linearity
Four serum samples containing different concentrations of phospholipase A 2 (92.81, 18.07, 15.21 and 4.33 μg/l) were diluted serially with assay buffer and analysed by TR-FIA. Excellent correlations (r = 0.99, 1.00, 1.00 and 0.99, respectively) were found in all four cases.
Reference interval
The mean concentration of phospholipase A 2 in the serum of 57 apparently healthy individuals (23 women, 34 men) was 5.8 μg/l (SD 1.4). Given the parametric distribution of this analyte, the 95% reference interval was 3.1-9.0 μg/l.
Ihter-niethod comparison
For comparison with a TR-FIA method using polyclonal sheep anti-phospholipase A 2 antibodies, the concentration of phospholipase A 2 in 67 sera (28 normal, 39 pancreatitis) was measured by both the TR-FIA methods. The new assay was found to correlate well with the comparison method. The results were: y = 0.803x + 3.24; r = 0.95, n = 67 ( fig. 6 ). 
Discussion
Phospholipase A 2 exists either s an extracellular secretory enzyme or s an intracellular enzyme. The bee and snake venom and pancreatic secretory phospholipases A 2 are typical extracellular enzymes. Intracellular phospholipases A 2 have been described in many cell types, and they exist either in soluble form in the cytosol, or they are membrane-bound in various subcellular compartments (12 -15) . Membrane-associated and soluble phospholipases A 2 differ in their Substrate specificity (14) and hydrophobic properties (15) , and they may also be functionally distinct. Membrane-bound phospholipases A 2 are believed to participate in the regulation of phospholipid metabolism in biomembranes including the biosynthesis of eicosanoids and the acylation-deacylation cycle of phospholipids (12 (Naja naja venom) and membrane-bound phospholipase A 2 from two different mammalian species and cell types (guinea pig alveolar macrophages and rat lymphocytes). In immunohistochemistry, the present monoclonal antibody 2E1 was found to be specific to pancreatic phospholipase A 2 . Iinmunoreactivity was found in human pancreatic acinar eells but not in other human tissues. We also investigated by TR-FIA the cross-reactivity of the monoclonal antibody 2E1 with non-pancreatic phospholipases A 2 (bee Venom and human ascitic fluid phospholipase A 2 ) and found no cross-reactivity. However, we found definite crossreactivity with pancratic phospholipases A 2 from other mammalian species. The antibody 2E1 reacted with rat and porcine pancreatic phospholipase A 2 , but it showed the highest affinity for human pancratic phospholipase A 2 . This finding confinns earlier observations that phospholipases A 2 from human, rat aiid porcine pancreas are closely related antigenically (2, 22) .
In the present study we developed a TR-FIA for the measurement of human pancreatic phospholipase A 2 based on the new monoclonal antibody 2E1, the latter being used äs the catching antibody in a solid-phase assay. The increased concentration of immunoreactive pancreatic phospholipase A 2 in serum is a specific and sensitive marker of acinar cell injury that occurs e. g. in acute pancreatitis. In our earlier study, we found increased serum phospholipase A 2 concentrations invariably at the early stages of both mild and severe forms of acute pancratitis (5). The phospholipase A 2 values were found to return to the reference interval at a somewhat slower rate than corresponding amylase activities in acute pancreatitis. The immunoreactive phospholipase A 2 may include the active enzyme, the enzymatically inactive proenzyme and/or degraded fragments of the active enzyme that may be catalytically active or inactive. Therefore immunoassays do not give any Information äs to the catalytic activity of the phospholipase A 2 enzyme molecule being measured. Since the catalytic activity of phospholipase A 2 correlates with the severity of the disease in acute pancratitis (6) , it is advisible to measure both the catalytic activity of phospholipase A 2 and the concentration of immunoreactive pancreatic phospholipase A 2 in the same serum samples in order to specifically detect pancreatic acinar cell injury (by the latter method) and to assess the severity of the disease process (by the former method). There is an ample selection of methods available for the determination of phospholipase A 2 catalytic activity (23).
The previously reported radioimmunoassays and the TR-FIA for measuring the concentration of human immunoreactive pancreatic phospholipase A 2 employ polyclonal antibodies raised in rabbits (1-3, 5) . The use of a monoclonal instead of a polyclonal antibody, however, would offer the advantage of unlimited supply, constant and predictable quality, and high specificity. Recently another RIA-method for the determination of pancreatic phospholipase A 2 employing a monoclonal antibody was described (4).
The mean (± SD) phospholipase A 2 value, 5.8 ±1.4 g/l, measured in sera of healthy individuals by the present TR-FIA agrees well with the phospholipase A 2 concentrations found by different immunoassays (RIA, TR-FIA): 6.5 ± 2.0 ^ (serum, 1), 5.1 + 1.7 §/1 (serum, 2), 4.3 ± 1.3 §/1 (plasma, 3), 2.4 ± 0.69 g/l (serum, 4) and 5.5 ±1.9 g/l (serum, 5). A good correlation between the present method and a TR-FIA described earlier by us (1) was found (data not shown). Likewise, measurements by the present method correlated very well (r = 0.95) with those obtained from the same normal and pathological serum samples by a method using a polyclonal sheep antibody both äs the catching and detecting antibody in a solid-phase TR-FIA (present study).
In summary, we describe a new monoclonal antibody 2E1 to human pancreatic secretory phospholipase A 2 showing no cross-reactivity with other human tissues or ascitic phospholipase A 2 . A specific TR-FIA method was developed to measure pancreatic phospholipase A 2 in serum samples.
